Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.
about
Kynurenine 3-Monooxygenase: An Influential Mediator of NeuropathologyThe human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and functionKynurenines in the mammalian brain: when physiology meets pathologyHost-microbiome interactions: the aryl hydrocarbon receptor and the central nervous systemContinuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult ratsBehavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment--role of brain kynurenic acid.Inflammation and the two-hit hypothesis of schizophrenia.Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intoleranceSystemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice.Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies.Tryptophan and kynurenic Acid may produce an amplified effect in central fatigue induced by chronic sleep disorder.Protracted maturation of forebrain afferent connections of the ventral tegmental area in the rat.Alternative kynurenic acid synthesis routes studied in the rat cerebellum.Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophreniaKynurenine pathway metabolism following prenatal KMO inhibition and in Mecp2(+/-) mice, using liquid chromatography-tandem mass spectrometry.Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memoryAltered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamineElevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia.Postpartum depression: psychoneuroimmunological underpinnings and treatment.Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantaminePerinatal complications and schizophrenia: involvement of the immune system.KCNH2-3.1 expression impairs cognition and alters neuronal function in a model of molecular pathology associated with schizophrenia.The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: Implications for schizophrenia.Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia.Preferential Disruption of Prefrontal GABAergic Function by Nanomolar Concentrations of the α7nACh Negative Modulator Kynurenic Acid.Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior.Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions.Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.Repeated LPS Injection Induces Distinct Changes in the Kynurenine Pathway in Mice.Tryptophan Metabolism and White Matter Integrity in Schizophrenia.Imbalanced kynurenine pathway in schizophrenia.Exposure to Kynurenic Acid during Adolescence Increases Sign-Tracking and Impairs Long-Term Potentiation in Adulthood.Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders.Protective Effects Induced by Microwave-Assisted Aqueous Harpagophytum Extract on Rat Cortex Synaptosomes Challenged with Amyloid β-Peptide.Maternal protein restriction during gestation and lactation in the rat results in increased brain levels of kynurenine and kynurenic acid in their adult offspring.Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood.Oral administration of a specific kynurenic acid synthesis (KAT II) inhibitor attenuates evoked glutamate release in rat prefrontal cortex.
P2860
Q26782867-3928B0AF-2996-4A0D-AB12-AE93EB420CBFQ26821785-4102C551-0870-4174-A157-6DB54F542DFAQ27003296-C3311D2D-2566-470D-AAA7-CD135C25D993Q28566343-F6C4C32E-2014-45B6-9725-51AEE7610E2BQ30408061-97B85FFA-3049-43D5-BCFC-2BB43B7908A6Q30419650-9C0DC93E-730A-4A16-9B7F-B660932FFAF4Q30422062-17F3230F-C10C-4232-9169-9101A4D31B7AQ30426795-D4B2C4E7-2EEF-4BD4-B549-1AC5AA83FCC1Q30654478-07457806-00FF-415D-B582-51F8EF47D4FBQ33572850-3F74957C-4810-4575-831B-3BE94DC8FD9BQ33688853-05B85760-3B7B-4348-A6DB-CDE0EF946C3DQ34441382-882729D1-9A68-4B50-A652-FD34D3B12050Q35618064-7BC3CF97-8CF1-49E8-AFE8-3456644C3AACQ35892576-0DE73B0B-7BEB-4CE7-A3FE-0DA1C5CB1CCCQ36131465-4C29A912-69B9-4969-B5E9-0D931E235FDFQ36244916-F9EC8193-5E68-48BE-98ED-71D7315D2058Q36273903-D9B573D2-C986-402C-9779-C8DDA7CE6EB1Q36515238-D7DB15C0-FDF4-4C44-9F49-84F5953F8F97Q36639113-DB707196-B04B-4C2C-8B33-2C04A12B8515Q36755954-ADB7D962-4E29-424E-987C-EAD90FD83234Q36952179-789F703D-5F2A-4AD1-AF65-A37063E69E86Q37165829-AB4178CA-CB92-4D4A-8A17-2D7A78B480DFQ37318862-ED1325AF-9F50-4B82-BEB0-7B37A9A7C03AQ37351984-AFEB6414-255A-4471-9F76-6BE7476628B7Q37580309-A0A15D24-7805-45EA-A3D3-A71CF547B114Q38253558-C0D65666-C4CF-4A63-8235-8A1F5801BED0Q38669116-A27ACB46-A9CC-4977-907A-694B7C8FAA36Q38761405-50B37886-4135-4086-8684-D526ACFA1B76Q38809444-CCFD7D05-7B62-4BCD-86F9-7D66A2FE2620Q39130393-637334E7-FC65-4E45-B426-66CD142ACEAFQ39777451-27FB6A0B-FC28-4E75-AA29-7A36BFE17C03Q41725053-02345F14-B713-4A19-8EF6-02B1DDC6F7C4Q42921229-AE33D0A3-968C-4775-B51E-986F1491D8C6Q43092673-28853B7C-BCB6-4CBC-BF6A-11DB9A7565B9Q46061752-D860612E-B1A0-468D-A962-A1E5FAEEC80BQ46346916-757104B7-337D-4B72-904E-7C35962DC1FEQ47902256-D5985AC0-3D05-44EE-8B42-4CF296F03245Q47973666-59FA4868-A674-464B-9B82-2F3C4162C2F6Q50331698-3FAAB329-8F12-4333-83BF-7DA0F048997A
P2860
Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.
@ast
Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.
@en
type
label
Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.
@ast
Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.
@en
prefLabel
Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.
@ast
Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.
@en
P2093
P2860
P1476
Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.
@en
P2093
Ana Pocivavsek
Greg I Elmer
Hui-Qiu Wu
John P Bruno
Robert Schwarcz
P2860
P304
P356
10.1111/J.1460-9568.2012.08064.X
P407
P577
2012-04-20T00:00:00Z